- Kelly, Abigail G;
- Wang, Weicang;
- Rothenberger, Eva;
- Yang, Jun;
- Gilligan, Molly M;
- Kipper, Franciele C;
- Attaya, Ahmed;
- Gartung, Allison;
- Hwang, Sung Hee;
- Gillespie, Michael J;
- Bayer, Rachel L;
- Quinlivan, Katherine M;
- Torres, Kimberly L;
- Huang, Sui;
- Mitsiades, Nicholas;
- Yang, Haixia;
- Hammock, Bruce D;
- Panigrahy, Dipak
Cancer therapy, including immunotherapy, is inherently limited by chronic inflammation-induced tumorigenesis and toxicity within the tumor microenvironment. Thus, stimulating the resolution of inflammation may enhance immunotherapy and improve the toxicity of immune checkpoint inhibition (ICI). As epoxy-fatty acids (EpFAs) are degraded by the enzyme soluble epoxide hydrolase (sEH), the inhibition of sEH increases endogenous EpFA levels to promote the resolution of cancer-associated inflammation. Here, we demonstrate that systemic treatment with ICI induces sEH expression in multiple murine cancer models. Dietary omega-3 polyunsaturated fatty acid supplementation and pharmacologic sEH inhibition, both alone and in combination, significantly enhance anti-tumor activity of ICI in these models. Notably, pharmacological abrogation of the sEH pathway alone or in combination with ICI counter-regulates an ICI-induced pro-inflammatory and pro-tumorigenic cytokine storm. Thus, modulating endogenous EpFA levels through dietary supplementation or sEH inhibition may represent a unique strategy to enhance the anti-tumor activity of paradigm cancer therapies.